Trogenix
Trogenix is a biotech company that develops precision cancer treatments that selectively target diseased cell states and behaviour.
Trogenix is a biotech company that develops precision cancer treatments that selectively target diseased cell states and behaviour.
Trogenix has raised $188M across 2 rounds. Its most recent round was a Series A of $94.1M in Oct 2025. Full funding history, investors, and team are detailed below.
Funding history
2 rounds on record — latest round shown, the rest unlock with a paid plan.
Unlock 1 earlier round — dates, amounts, round types — plus the lead investor for every round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Trogenix is featured in
Similar companies
Aerska is a biotechnology company that is creating RNA medications to treat, postpone, and prevent brain disorders.
Weike Bio is a gene therapy drug development company.
Twinpig Biolab researches and develops anticancer drugs.
Solve Therapeutics is a biopharmaceutical company that develops Antibody Drug Conjugate and Bispecific Therapeutics.
Kunshi Biotechnology is a drug developer with an emphasis on solid tumor cells.
Lifordi Immunotherapeutics is a biotech company that provides antibody-drug conjugates for autoimmune and inflammatory disorders.
Artizan Biosciences focuses on drug discovery and development for diseases involving the human intestinal microbiota.
Neok Bio is a biotech startup that focuses on bispecific ADCs in cancer therapy.
BOOST Pharma develops a stem cell therapy for the treatment of osteogenesis imperfecta.
Step Pharma is a biotechnology company.
TORL BioTherapeutics is a clinical-stage biopharmaceutical business.
ThirdLaw Molecular pioneers revolutionary Spiroligomer™ molecules for safer, more targeted, effective disease treatment.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.